US FDA Eases Mandatory Reporting Burden For Drug Importers
Executive Summary
At the end of the year, the burden will shift from FDA to industry to provide automated screening data for US imports of drugs and other FDA-regulated goods as part of government-wide effort to establish a ‘single window’ for import clearance that was accelerated by a presidential executive order. Final FDA rule eases some of the burden and agency offers 24/7 compliance help.